Table of Contents
Chapter 1 Cancer Gene Therapy Market: Methodology And Scope
1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: CAGR Calculation
1.8 Regional Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.11 List of Abbreviations
Chapter 2 Cancer Gene Therapy Market: Executive Summary
2.1 Cancer Gene Therapy Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Cancer Gene Therapy Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 High growth of the pharmaceutical industry
3.3.1.2 Rising R&D investements and demand for novel cancer therapeutics
3.3.1.3 Increased incidence of cancers
3.3.1.4 Technological advancements
3.3.2 Market Restraint Analysis
3.3.2.1 High product prices
3.3.2.2 Unethical use of gene therapy
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis – Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Cancer Gene Therapy Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2021
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Cancer Gene Therapy Market: Therapy Analysis
5.1 Cancer Gene Therapy Market: Therapy Movement Analysis
5.2 Oncolytic Virotherapy
5.2.1 Oncolytic virotherapy market estimates and forecast, 2018 – 2030 (USD Million)
5.3 Gene Induced Immunotherapy
5.3.1 Gene induced immunotherapy market estimates and forecast, 2018 – 2030 (USD Million)
5.4 Gene Transfer
5.3.1 Gene transfer market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 6 Cancer Gene Therapy Market: End-Use Analysis
6.1 Cancer Gene Therapy Market: End-Use Movement Analysis
6.2 Research Institutes
6.2.1 Research institutes based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.3 Biopharmaceutical Companies
6.3.1 Biopharmaceutical companies based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.4 Diagnostic Centres
6.4.1 Diagnostic centres based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
6.5 Other End-use
6.5.1 Other end-use based cancer gene therapy market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 7 Cancer Gene Therapy Market: Regional Business Analysis
7.1 Market Share Analysis by Country, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.5 South Korea
7.1.3.5.1 South Korea market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.6 Australia
7.1.3.6.1 Australia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5 Middle East And Africa
7.1.5.1 Middle East & Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.2 South Africa
7.1.5.2.1 South Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.4 UAE
7.1.5.4.1 UAE market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 8 Cancer Gene Therapy Market: Company Profiling
8.1 Company Profiles
8.1.1 Abeona Therapeutics Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Asklepios BioPharmaceutical Inc.
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Celgene(Bristol-Myers Squibb Company)
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Elevate Bio
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 GlaxoSmithKline Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Bluebird bio Inc.
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Genelux Corporation
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 OncoGenex Pharmaceuticals Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Introgen Therapeutics Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Altor Bioscience Inc.
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Merck & Co., Inc.
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 GenVec
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
8.1.13 BioCancell Inc.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic initiatives
8.2 List of Other Key Players